A multi-institutional database to stimulate new research protocols, identify potential need for future expansion of the network to incorporate additional patient populations, and provide a descriptive understanding of children with hydrocephalus cared for within the network.
The study uses a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing, targeted panel profile, and RNA-Seq to test the efficacy of such an approach in children with high-grade gliomas.
A phase I trial studying the side effects of nivolumab before and after surgery in treating children and young adults with high-grade glioma that has come back or is increasing in scope or severity.
The objective of this study is to ensure that patients with localized central nervous system non-germinomatous germ cell tumors treated with induction chemotherapy followed by response evaluation and whole ventricular + spinal canal irradiation maintain excellent 2-year progression free survival.
The study hypothesizes that use of cabozantinib in pediatric patients with ultra-high-risk solid tumors with minimal disease burden can prevent or slow recurrent tumor formation and significantly extend the period of disease control.
A phase III study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment.
A multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years old with newly diagnosed medulloblastoma.
This study aims to demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival is non-inferior compared with treatment with carboplatin/vincristine in previously untreated low-grad glioma.